Join to View Full Profile
Division of Leukemia1500 East Duarte RoadDuarte, CA 91010
Phone+1 626-256-4673
Fax+1 626-389-3058
Dr. Ali is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Haris Ali is an oncology specialist based in Duarte, CA, with a subspecialty in hematologic oncology. He completed his medical education at Rawalpindi Medical College and furthered his training with a residency and internship in internal medicine, followed by fellowships in hematology, medical oncology, and hematopoietic cell transplantation. Since 2012, he has served as a staff physician and instructor at the City of Hope Comprehensive Cancer Center. His expertise encompasses myelofibrosis, hematopoietic stem cell transplantation, chronic neutrophilic leukemia, and multiple myeloma. Dr. Ali has contributed to several publications on topics including allogeneic transplantation and graft-versus-host disease and is involved in clinical trials focused on stem cell transplantation for various hematologic conditions.
Education & Training
City of Hope National Medical CenterFellowship, Hematopoietic Cell Transplantation, 2012 - 2013
University of Texas Southwestern Medical CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
Loma Linda University Health Education ConsortiumResidency, Internal Medicine, 2004 - 2006
MedStar Health Georgetown University/Harbor HospitalInternship, Internal Medicine, 2003 - 2004
Rawalpindi Medical CollegeClass of 2001
Certifications & Licensure
CA State Medical License 2005 - 2027
TX State Medical License 2009 - 2026
American Board of Internal Medicine Hematology
Clinical Trials
- Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis Start of enrollment: 2016 Nov 13
- Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation Start of enrollment: 2020 Nov 11
Publications & Presentations
PubMed
- Belumosudil for the treatment of chronic graft-versus-host disease: a single center real-world experience.Badri Modi, Dat Ngo, Jason Chen, Dongyun Yang, Haoyue Shan
Bone Marrow Transplantation. 2025-04-01 - Correction: Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002.Gabrielle Meyers, Mehdi Hamadani, Michael Martens, Haris Ali, Patrice Chevallier
Bone Marrow Transplantation. 2025-02-27 - Melphalan-based conditioning with post-transplant cyclophosphamide for peripheral blood stem cell transplantation: donor effect.Paul B Koller, Tamer Othman, Dongyun Yang, Sally Mokhtari, Yazeed Samara
Bone Marrow Transplantation. 2025-02-27
Abstracts/Posters
- Spred1 Insufficiency in the Hematopoietic and/or Vascular Compartments of the Bone Marrow (BM) Niche Promotes Aggressive Leukemogenesis in Chronic Myelogenous Leukemia...Haris Ali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administr...Haris Ali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplan...Haris Ali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Clinical Outcomes of MDS Patients Who Were Allogeneic Hematopoietic Stem Cell Transplant Candidates but Did Not Proceed with Transplantation2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
City of Hope Doctors and Scientists Present Research on Novel Cancer Therapies at American Society of Hematology (ASH) Annual ConferenceDecember 10th, 2024
City of Hope Scientists Present Potential New Treatments for Chronic Lymphocytic Leukemia, Myelofibrosis and Other Diseases at American Association of Cancer Research (AACR) Annual MeetingApril 17th, 2023- Adding Itacitinib to Conventional GVHD ProphylaxisDecember 9th, 2022
- Join now to see all
Professional Memberships
- Member
- American Society for Blood and Marrow TransplantationMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
